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Abstract
Background
Hypothyroidism is often diagnosed, and subsequently treated, due to health-related quality
of life (HRQL) issues. However, HRQL following treatment has never previously been
assessed in longitudinal descriptive studies using validated instruments.
Objective
To investigate disease-specific (ThyPRO) and generic (SF-36) HRQL, following levothyrox-
ine therapy in patients with hypothyroidism due to autoimmune thyroiditis.
Methods
This prospective cohort study was set at endocrine outpatient clinics at two Danish univer-
sity hospitals. Seventy-eight consecutive patients were enrolled and completed HRQL
questionnaires before, six weeks, and six months after initiation of levothyroxine therapy.
Normative ThyPRO (n = 739) and SF-36 (n = 6,638) data were available for comparison
and changes in HRQL following treatment were estimated and quantified.
Results
Prior to treatment, all ThyPRO scales were significantly impacted (p<0.0001), compared to
the general population sample. The same was observed for seven of eight SF-36 scales,
the exception being Bodily Pain. Tiredness (ThyPRO) and Vitality (SF-36) were the most
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markedly impacted scales. After six weeks of treatment, nine of thirteen ThyPRO scales
had significantly improved. ThyPRO improvements were consistent at six months, where
five of eight SF-36 scales had also significantly improved, but deficits persisted for a subset
of both ThyPRO and SF-36 scales.
Conclusions
In this population of hypothyroid patients, HRQL was widely affected before treatment, with
tiredness as the cardinal impairment according to both ThyPRO and SF-36. Many aspects
of HRQL improved during the first six months of LT4 therapy, but full recovery was not
obtained. Our results may help clinicians inform patients about expected clinical treatment
effects.
Introduction
Chronic autoimmune or Hashimoto’s thyroiditis (AIT) is common, and accounts for 85% of
all cases of overt hypothyroidism in Denmark, where the overall annual incidence is approxi-
mately 47.2/100,000 [1,2]. The standard treatment is life-long levothyroxine (LT4) therapy,
adjusting the dosage to achieve normal circulating thyrotropin (TSH) levels [3]. However,
recent investigations suggest that LT4 cannot ensure a euthyroid state in all tissues simulta-
neously [3], and cross-sectional studies have reported impaired psychological well-being and
cognitive functioning in euthyroid AIT patients on LT4 [4–7]. Health-related quality of life
(HRQL), measured by reported outcomes (PROs), is increasingly used when evaluating treat-
ment effects in clinical studies and practice [8]. Instruments can be divided into disease-specific
and generic questionnaires. Combining the two types of measurement maximizes precision
and sensitivity, and allows for comparability and interpretation across different patient groups
and populations [9,10]. Measurement properties have been well-described for the most widely
used generic instrument, SF-36 [11,12], while some currently available disease-specific instru-
ments (4,6) have undergone initial validation in hypothyroid patients [6,13,14]. To further
improve the measurement of HRQL in thyroid diseases, our group developed and validated the
disease-specific ThyPRO questionnaire [15–20]. In AIT, HRQL has never previously been
measured in descriptive longitudinal studies, and ThyPRO was chosen for this purpose since it
is the only HRQL instrument that has been validated for responsiveness to treatment [21].
The objective of this prospective cohort study was therefore to investigate disease-specific
(ThyPRO) and generic (SF-36) HRQL in patients with AIT before, during, and after six months
of medical therapy with LT4, comparing their HRQL with that found in representative general
population samples.
Materials and Methods
Design, setting and participants
This study was a prospective cohort study carried out from October 2008 to May 2012. Patients
referred for hypothyroidism were consecutively recruited from the endocrine outpatient clinics
at Copenhagen University Hospital, Rigshospitalet, and Odense University Hospital. The
inclusion criteria were18 years of age; indication for LT4 therapy treatment (patients had to
be untreated at inclusion); positive thyroid peroxidase (TPO-Ab) and/or thyroglobulin (Tg-
Ab) antibody concentrations according to local clinical guidelines; TSH concentrations>4.0
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mIU/L; ability to complete paper-and-pencil questionnaires in Danish. Exclusion criteria were
pregnancy and/or breastfeeding; thyroid cancer; previous radioiodine treatment or thyroid sur-
gery; major comorbidities rendering completion of the study or interpretation of results
improbable.
Follow-up
All patients were treated and followed according to local clinical guidelines, with regular blood
sampling and visits in the outpatient clinics. After initiation of LT4 therapy, the dosage was
adjusted aiming for TSH levels within the reference ranges. At Odense University Hospital, a
booklet containing two questionnaires (ThyPRO and SF-36 v2) and additional questions on
sociodemographics, comorbidity, and non-thyroid medication was handed out at the first visit.
At Rigshospitalet, the same booklet was sent to eligible patients; after two weeks a reminder
was sent to non-responders. Patients completed the ThyPRO questionnaire prior to and six
weeks and six months after initiation of treatment with LT4, and the SF-36 v2 questionnaire
prior to and six months after commencement of therapy. ThyPRO data after six weeks of LT4
therapy was originally collected for methodological purposes in connection with the validation
of the ThyPRO instrument [21], but provided extra data in this clinical study. For the same rea-
son SF-36 was not collected in this cohort at six weeks. The questionnaires were collected by
mail. Clinical data on diagnosis, treatment and biochemical variables were obtained by medical
chart review. Biochemical variables included serum TSH (reference range: 0.3–4.0 mIU/L),
total serum thyroxine (T4) (65–135 nmol/L), serum TPO-Ab (<30 mIU/L) and serum Tg-Ab
(<20 mIU/L). Subclinical hypothyroidism was defined as TSH concentrations above the refer-
ence range with T4 within the reference range, and overt hypothyroidism as TSH above the ref-
erence range and T4 below the reference range.
A subset of the data has previously been used for a methodological evaluation of the respon-
siveness of the ThyPRO questionnaire [21].
Outcomes
ThyPRO consists of 85 items on physical, mental and social domains of functioning and well-
being in hypothyroidism, hyperthyroidism, non-toxic goiter, and Graves’ orbitopathy. The
items employ a recall period of four weeks and are summarized in 13 multi-item scales and one
single-item scale concerning Overall Impact of thyroid disease on HRQL. Each scale ranges
0–100, with higher scores indicating poorer health status. For specific items, please see the
entire ThyPRO questionnaire (S1 Appendix).
The SF-36 consists of 36 items, also using a four week recall period, summarized in 8 scales.
The scale scores can be further aggregated into physical and mental component summary
scores. SF-36 scores were standardized using norm-based scoring to facilitate the comparison
between SF-36 v1 (used in the general population sample) and v2 (used in the patient popula-
tion). With norm-based scoring, mean and standard deviation (SD) is standardized to 50 and
10, respectively, in the general US population and higher scores indicate better health status.
General population samples
ThyPRO data from the Danish general population were gathered from a random sample of
adult citizens, using the Danish Civil Registration System, as previously described [22]. The
questionnaire included items from the nine scales of the ThyPRO survey, which do not attri-
bute HRQL-impact specifically to thyroid disease (in contrast to scales on impact of thyroid
disease [Impaired Social Life, Daily Life, Sexlife, and Cosmetic Complaints]). The general
population questionnaire also addressed socio-demographic variables, comorbidity, and
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medication. SF-36 data from the Danish general population were derived from the Danish
Health Interview Survey in 2005, as described elsewhere [23,24]. For the present study we
included general population data only for respondents living in the three regions from which
patients were recruited.
Statistical analysis
To address a potential selection bias, the available socio-demographic baseline characteristics
of non-responders and responders were compared using the Wilcoxon-Mann-Whitney (age)
and Chi-square (gender, education, chronic disease). Changes in mean HRQL scale scores and
biochemical measurements between baseline and six weeks and six months after initiation of
LT4 therapy were analyzed with the paired Student’s t-test. Multiple linear regression analyses,
adjusted for age, gender, comorbidity and educational status were performed to test for differ-
ences in HRQL scale scores between patients and the general population samples, for associa-
tions between HRQL scale scores and TSH, T4 and TPO-Ab concentrations, respectively, and
to compare baseline HRQL scale scores between participants completing follow-up surveys,
and those lost to follow-up. Biochemical measurements within the four week recall period were
used for analyses. The magnitude of differences between the general population and patient
samples was evaluated by effect sizes, calculated as the mean difference divided by the pooled
SD of the general population sample and the patients at baseline. The magnitude of changes in
patient scores following treatment was evaluated by effect sizes calculated as the mean change
divided by the SD in the patient sample at baseline. In accordance with Cohen, an effect size of
0.2–0.5 was defined as small, 0.5–0.8 as moderate and>0.8 as large [25]. P-values<0.05, were
considered significant. All analyses were performed using SAS 9.4.
Ethical considerations
According to Danish law, questionnaire studies do not require and thus cannot obtain approval
by ethical committees. A completed, returned questionnaire is regarded as consent. The study
was approved by the Danish Data Protection Agency (#2007-58-0015) and conducted in accor-
dance with the Declarations of Helsinki.
Results
Participants
During 43 months, consecutive patients were screened and 100 patients with AIT were invited
to participate. Seventy-eight patients completed the baseline (pre-treatment) survey (response
rate 78%). In all, 63 patients completed follow-up surveys at six months, yielding a follow-up
response rate of 81% of initially responding patients. The SF-36 was included in the surveys
only after December 2009 and thus, 68 patients completed the SF-36 survey at baseline, and 58
(85% of initially responding patients) at six months. The median baseline age was 47 years, and
90% were females. All patients were treated with LT4 during the six-month study period.
Socio-demographic characteristics, educational status, and comorbidity are shown in Table 1.
There were no significant differences in baseline socio-demographic characteristics, biochemi-
cal measurements, or HRQL between the fifteen patients who completed only the baseline
questionnaire and those completing the entire survey.
Biochemical measurements
At baseline, the median (interquartile range) TSH was 8.1 (5.5–12.2) mIU/L, T4 was 82 (72–
99) nmol/L, and TPO-Ab was 526 (221–1590) mIU/L. One participant had negative TPO-Ab
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but positive Tg-Ab concentration at 68 mIU/L. At baseline, 66 patients had subclinical and 12
patients had overt hypothyroidism. After six weeks of LT4 therapy, serum TSH significantly
decreased (P<0.0001) to a median (interquartile range) of 3.0 (1.7–4.4) mIU/L, further
decreasing to 2.6 (1.4–4.2) mIU/L at six months. T4 significantly increased (P<0.0001), as
compared with baseline, with median (interquartile range) concentrations of 104 (92–117)
nmol/L and 102 (80–118) nmol/L after six weeks and six months, respectively. After
six months, 24 patients still had elevated serum TSH, 21 of whom had subclinical
hypothyroidism.
HRQL
ThyPRO and SF-36 scale scores for patients at baseline and follow-up, and for general popula-
tion samples are shown in Tables 2 and 3, and further illustrated in Figs 1 and 2, respectively.
Comparison with general population samples before treatment. Baseline ThyPRO
scores among patients were significantly higher (worse) than the general population scores in
all nine comparable scales (p-values<0.0001). Differences varied, from small effect sizes for
Eye Symptoms and Anxiety to large effect sizes for Goiter Symptoms, Tiredness, and Emo-
tional Susceptibility. The most severely impaired scale was the Tiredness scale (effect size:
1.05). Patients’ baseline SF-36 scores were lower (worse) than those in the general population
sample in seven of eight scales, with effect sizes ranging from small to large, except for the
Bodily Pain scale, where there was no difference. Large differences were seen in the Mental
Health and Vitality scales, and the Mental Component summary score, with the largest differ-
ence for Vitality (effect size 1.37). There was no difference between patients and the general
population sample in the SF-36 Physical Component summary.
Changes following medical therapy. Scores significantly decreased (improved) for nine
of thirteen ThyPRO scales as well as for overall HRQL after six weeks of therapy. All improve-
ments, except Impaired Sexlife, were consistent after six months of therapy with additional sig-
nificant improvements observed for the Depressivity and Cosmetic Complaints scales. All
significant changes in the ThyPRO multi-item scales were of small magnitude, while the overall
HRQL item improved with a moderate effect size, after six months of therapy (p<0.0001).
Table 1. Baseline sociodemographic characteristics of patients with autoimmune thyroiditis (AIT) and general population samples.
AIT (n = 78) General population ThyPRO (n = 739) General population SF-36 (n = 6,638)
Women (n (%)): 70 (90) 602 (81) 3,605 (54)
Age in years (median (range)) 47 (18–91) 50 (19–81) 50 (18–99)
Education (n (%))a
10 years 10 (13) 129 (17) 1,133 (17)
11–14 years 25 (32) 313 (42) 3,679 (55)
15 years 34 (44) 249 (34) 1,695 (26)
No information 9 (11) 48 (7) 131 (2)
Chronic disease (n (%))b
No chronic disease 53 (68) 499 (68) 4,024 (61)
1 chronic disease 18 (23) 165 (22) 1,706 (26)
2 chronic diseases 7 (9) 75 (10) 908 (14)
Table 1 legend:
aCombined school and professional education classiﬁed in accordance with the International Standard Classiﬁcation of Education (www.uis.unesco.org).
bIncludes: asthma, diabetes, ischaemic heart disease, stroke, chronic obstructive pulmonary disease, osteoarthritis, gastric/duodenal ulcer, anxiety and
depression, other psychiatric diseases, chronic back pain and other conditions of the back.
doi:10.1371/journal.pone.0156925.t001
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Six months after initiation of LT4 therapy, the SF-36 scales for Role-Physical, Bodily Pain,
Vitality, Social Functioning and Mental Health, and the Mental Component summary score,
had improved significantly, all with small effect sizes.
Comparison with general population samples at follow-up. According to ThyPRO,
there were no longer any large differences after six weeks of treatment, as compared with the
general population samples. However, significant moderate differences persisted in physical
Table 2. ThyPRO scale scores.
ThyPRO scales General
Population
Patients with autoimmune thyroiditis
(n = 739) Baseline (n = 78) Six weeks (n = 61) Six months (n = 63)
Score Score Difference vs.
GP
Score Difference vs.
GP
Change from
baseline
Score Difference vs.
GP
Change from
baseline
Goiter Symptoms 5 (9) 14
(15)
9+++ 9 (12) 4+ -4 (13)+ 8 (10) 3+ -5 (13)+
Hyperthyroid
Symptoms
12 (14) 20
(16)
8++ 14
(15)
2 -5 (13)+ 14
(13)
2+ -4 (12)+
Hypothyroid
Symptoms
14 (16) 27
(24)
13++ 25
(23)
11++ -1 (18) 23
(21)
9++ -2 (16)
Eye Symptoms 8 (11) 13
(14)
5++ 9 (10) 1 -3 (9)+ 9 (11) 1 -3 (9)+
Tiredness 35 (21) 58
(28)
23+++ 47
(26)
12++ -10 (23)+ 43
(27)
8+ -12 (23)+
Cognitive
Complaints
14 (17) 27
(26)
13++ 22
(23)
8+ -3 (23) 22
(23)
8+ -3 (19)
Anxiety 13 (16) 21
(20)
8+ 13
(14)
0 -6 (17)+ 11
(17)
-2 -7 (15)+
Depressivity 21 (18) 32
(23)
11++ 27
(20)
6+ -4 (18) 25
(19)
4+ -5 (20)+
Emotional
Susceptibility
23 (19) 40
(25)
17+++ 29
(24)
6+ -8 (20)+ 28
(22)
5+ -10 (18)+
Impaired Social
Life
- 13
(19)
- 10
(15)
- -4 (16)+ 8 (15) - -5 (17)+
Impaired Daily
Life
- 22
(27)
- 14
(21)
- -8 (18)+ 12
(20)
- -9 (20)+
Impaired Sexlife - 23
(30)
- 16
(25)
- -6 (22)+ 17
(23)
- -6 (31)+
Cosmetic
Complaints
- 20
(21)
- 17
(23)
- -4 (17) 14
(18)
- -6 (16)+
Overall HRQL - 37
(36)
- 25
(28)
- -13 (30)+ 19
(26)
- -18 (34)++
Table 2 legend and notes: Mean (SD) ThyPRO scale scores (0–100, higher scores indicating worse HRQL) of the general population (GP) sample and
patients with autoimmune thyroiditis at baseline (before treatment) and at follow-up (six weeks and six months after initiation of LT4 therapy). Differences
between patients and the general population sample were analyzed with multiple linear regression analysis, adjusting for age, sex, comorbidity, and
educational status. Changes between baseline and follow-up for patients completing the questionnaire at both assessments were analyzed with the paired
t-test. Discrepancies between mean scores and mean changes were due to the 15 responders lost to follow-up. Magnitudes of changes were evaluated
by effect sizes (mean difference/SDbaseline). Items in ﬁve ThyPRO scales (Impaired Social Life, Impaired Daily Life, Impaired Sexlife, Cosmetic
Complaints, and Overall Quality of Life) are asked with attribution to thyroid disease and cannot be answered by respondents from the general population.
Statistically signiﬁcant differences (P<0.05) are marked in bold.
+Small effect size (0.2–0.5)
++Moderate effect size (0.5–0.8)
+++Large effect size (>0.8), according to Cohen et al. [25].
doi:10.1371/journal.pone.0156925.t002
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Hypothyroid Symptoms and Tiredness, as did small differences in Goiter Symptoms and Cog-
nitive Complaints. After six months, the same four scales remained significantly different from
the general population sample. Only the Hypothyroid Symptoms scale attained a moderate
effect size at this time point, while the other deficits were of small magnitude.
After six months of LT4 therapy several of the SF-36 scales, i.e. Mental Health, Role-Emo-
tional, Social Functioning, Vitality, and the Mental Component, were still significantly
impaired compared to the general population, showing moderate to small effect sizes.
Table 3. SF-36 scale scores.
SF-36 scales GeneralPopulation Patients with autoimmune thyroiditis
(n = 6,638) Baseline (n = 68) Six months (n = 58)
Score Score Difference vs GP Score Difference vs GP Change from baseline
Physical Functioning 52 (8) 50 (8) -2+ 51 (9) -1 0 (6)
Role-Physical 51 (9) 47 (10) -4+ 50 (9) -1 3 (8)+
Bodily Pain 53 (10) 52 (12) -1 55 (10) 2 3 (9)+
General Health 53 (9) 49 (10) -4+ 49 (11) -4+ 1 (6)
Vitality 56 (10) 43 (13) -13+++ 49 (13) -7++ 6 (11)+
Social Functioning 54 (8) 49 (12) -5++ 51 (11) -3+ 3 (8)+
Role-Emotional 51 (9) 45 (12) -6++ 47 (12) -5++ 2 (11)
Mental Health 54 (9) 47 (9) -7+++ 50 (10) -4++ 4 (8)+
SF-36 summary scores
Physical Component 51 (9) 51 (10) 0 52 (8) 1 1 (6)
Mental Component 54 (8) 44 (12) -10+++ 48 (11) -6++ 4 (9)+
Table 3 legend and notes: Mean (SD) norm-based SF-36 scale scores (higher scores indicating better HRQL) of the general population sample (GP)
and patients with autoimmune thyroiditis at baseline (before treatment) and at follow-up (six months after initiation of LT4 therapy). Differences between
patients and the GP sample were analyzed with multiple linear regression analysis, adjusting for age, sex, comorbidity, and educational status. Changes
between baseline and follow-up for patients completing the questionnaire at both assessments were analyzed with the paired t-test. Discrepancies
between mean scores and mean changes were due to the 10 responders lost to follow-up. Magnitudes of changes were evaluated by effect sizes (mean
difference/SDbaseline). Statistically signiﬁcant differences (P<0.05) are marked in bold.
+Small effect size (0.2–0.5)
++Moderate effect size (0.5–0.8)
+++Large effect size (>0.8), according to Cohen et al. [25].
doi:10.1371/journal.pone.0156925.t003
Fig 1. ThyPRO radar plot. Radar plot showing ThyPRO scale scores for patients with autoimmune
hypothyroidism (AIT) at baseline and 6-months follow-up as well as scores from the general population
sample. Each scale ranges 0–100, with higher scores indicating poorer quality of life. Items in ThyPRO
scales marked* are asked with attribution to thyroid disease and cannot be answered by respondents from
the general population.
doi:10.1371/journal.pone.0156925.g001
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Associations between biochemical measurements and HRQL
There were no significant associations between serum levels of TSH, total T4 or TPO-Ab and
any of the ThyPRO or SF-36 scores, neither at baseline nor during follow-up. Neither were
there any differences in the scores or effect of treatment, when comparing patients with sub-
clinical (n = 66) versus overt hypothyroidism (n = 12) at baseline or follow-up.
Discussion
In this prospective cohort study, we have assessed HRQL in patients with AIT. For the first
time HRQL has been measured longitudinally in hypothyroid patients with both validated dis-
ease-specific (ThyPRO) and generic (SF-36) surveys, and compared with HRQL data from gen-
eral population samples. Prior to LT4 therapy, we found significant impacts of varying
magnitude across disease-specific (ThyPRO) and generic (SF-36) HRQL aspects, as compared
to general population samples. Impairments ranged from large differences for Tiredness to
small differences for Physical Functioning, while Bodily Pain was the only unaffected scale.
The wide array of impacts was corroborated in a recent population-based case-control study of
newly diagnosed overt AIT, with tiredness being the most frequently reported symptom [26].
Since volunteer control subjects also experienced many symptoms indicative of hypothyroid-
ism, the authors found that neither presence nor absence of individual symptoms is reliable for
diagnosis of the disease [26]. In addition, there were no associations between symptom burden
and biochemical markers at disease onset [26]. Thus, tiredness may be reported irrespective of
disease or biochemical disease severity. Nevertheless, our study quantifies that tiredness is
severely impacted in newly diagnosed AIT patients, as compared with the general population.
After six weeks of treatment, we found a partial remission of the disease-specific tiredness,
which further ameliorated at six months. However, a small to moderate impairment persisted,
also when measured by the SF-36 Vitality scale. Thus, rather than reporting tiredness as a pres-
ent/absent symptom, as is the classical diagnostic medical approach, quantifying it on a contin-
uum, as done with ThyPRO, offers a more detailed picture of the course of disease
symptomatology.
Deficits persisted for a subset of other disease-specific and generic scales. The ThyPRO scale
showing the largest deficit at six months was the physical Hypothyroid Symptoms scale,
including items such as “Have you been sensitive to cold?” and “Have you had dry skin?” This
Fig 2. SF-36 Radar plot.Radar plot showing SF-36 scale scores for patients with autoimmune
hypothyroidism (AIT) at baseline and 6-months follow-up as well as scores from the general reference
population. Higher scores indicate better health status.
doi:10.1371/journal.pone.0156925.g002
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scale, along with Cognitive Complaints, did not respond to treatment during the study period.
However, it has been suggested that persisting cognitive complaints, even in patients with sub-
clinical hypothyroidism (the majority of our participants), are most likely an independent
entity requiring separate evaluation [27]. Another aspect of particular interest is the poorly
understood relationship between hypothyroidism and depression [28]. In a recent study both
depressive symptoms and sexual dysfunction were related to subclinical hypothyroidism in
female patients with AIT [29]. We found depressivity moderately impacted in the untreated
state, but this item improved during follow-up and was not significantly different, as compared
with the general population, at the end of the study. The severity of sexual dysfunction cannot
be compared with the general population in our study, as items in the ThyPRO scale for sexual
impairments are asked with attribution to thyroid disease, and therefore irrelevant to the gen-
eral population.
Many disease-specific issues significantly improved already within six weeks, with further
improvements after six months, when the majority of SF-36 scales were also improved. All sig-
nificant improvements were of small magnitude, except the ThyPRO overall HRQL item that
improved with a moderate effect size at six months. This item asks the question: “During the
past four weeks, has your thyroid disease had a negative effect on your quality of life?” It could
be speculated that small improvements in various aspects accumulate, and lead to a larger over-
all effect.
Interestingly, we found similar impact and treatment effects when comparing patients with
subclinical and overt hypothyroidism, supporting that also patients with mild biochemical thy-
roid failure benefit from treatment, at least from a HRQL point of view. This study was imple-
mented in the daily-life clinic, reflected by the fact that approximately 30% of the patients had
a TSH level above the reference range after six months of therapy. This is well in line with the
Colorado thyroid disease prevalence study, where 40% of patients taking thyroid medication
had abnormal TSH levels [30]. Thus, suboptimal LT4 dose or poor patient compliance seems
to be the rule and not unique to our study. It could be speculated that obtaining euthyroidism
might have resulted in more pronounced HRQL improvements. However, we found no associ-
ations between thyroid function and HRQL in our regression analyses, and previous observa-
tions also suggest that normalization of TSH with LT4 does not safeguard against persistent
complaints [3]. Here, biochemical data, used for the regression analyses, were obtained by
medical chart review. Future long-term studies should prospectively standardize the timing
between measurement of HRQL and serum markers of thyroid function, in order to further
elaborate the relationship between biochemical dysfunction and HRQL.
Strengths of our study are its longitudinal design, the use of validated disease-specific and
generic questionnaires, and inclusion of general population reference groups. This conceptual
framework can readily be applied to the study of quality of life in other diseases. However,
there are also limitations. Although individuals lost to follow-up had similar sociodemographic
characteristics they tended to have more impaired HRQL, albeit not statistically significant, as
compared with patients who had a full survey. Three of fifteen patients (20%) lost to follow-up
had overt hypothyroidism at baseline, while this number was 9/63 (14%) in patients with a full
survey (9/63). This, as well as recruitment solely from university hospital outpatient clinics,
may have induced selection bias. Generally, there was consistency between significance tests
and effect sizes, but a minority of small differences or changes did not reach statistical signifi-
cance, which may be caused by lack of power. We considered applying formal corrections for
multiple comparisons, but decided not to, because the results were consistent [31] with multi-
ple comparisons pointing towards the same conclusion (illustrated by Figs 1 and 2), and to
avoid type II errors. Lack of power may explain the absence of associations between the degree
of thyroid dysfunction and HRQL, as e.g. only 12 patients had overt hypothyroidism at
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baseline. Finally, although hypothyroidism–also when adequately treated–is associated with
increased morbidity and mortality [32–34], we cannot rule out that HRQL issues would have
improved further with longer follow-up. Extended follow-up could also have helped to unmask
a potential response bias of participants knowingly being started on LT4. Disfavoring such a
bias, the improvements at six weeks were, with one exception, consistent at six months.
Despite the limitations mentioned, our data can help clinicians inform hypothyroid patients
what to expect, when starting on LT4 therapy. Benefits of addressing the patient perspective in
medical communication are well established [35] and future studies should investigate whether
HRQL assessment in clinical practice can improve the care for hypothyroid patients [36].
Recent investigations encourage initiatives that stimulate ethical placebo mechanisms in clini-
cal practice. HRQL assessment could do so by contributing, in a positive manner, to the overall
therapeutic context [37]. To advance its applicability, both in clinical practice and research, we
have recently developed a short version of ThyPRO [38]. It constitutes the primary outcome in
our on-going randomized controlled trial of selenium supplementation in AIT [39], and can be
put to ideal use in future trials investigating various formulations of LT4 and/or combinations
with liothyronine [3] or placebo-controlled trials in subclinical hypothyroidism [28].
In conclusion, untreated hypothyroid patients experience widely impacted HRQL, com-
pared to the general population. Most aspects improve during the first six months of LT4 ther-
apy but some deficits remain, including tiredness, which is the cardinal manifestation.
Whether full remission in HRQL, with this or any combination of LT4 and liothyronine, will
ensue with longer follow-up remains to be explored.
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